Construction at the new site will begin early next year and is expected to be complete in 2010. Upon completion, the total square footage of the Billerica Campus will be approximately 210,000 square feet, including more than 160,000 square feet of lab space.
"We will harness the power of our scientific expertise and understanding of disease biology, and leverage the significant amount of academic and healthcare resources available to us in nearby Boston, to further strengthen our dedication to finding new and innovative treatments that improve the quality of life for people living with serious diseases," says Bernhard Kirschbaum, head of global research for Merck Serono.
The US headquarters of EMD Serono will remain in Rockland. The company will strengthen its leadership position in its current therapeutic areas of Neurodegenerative Diseases and Endocrinology, and build the necessary infrastructure to support an increase in US clinical trials, as well as commercial growth in new areas of expertise, including cancer and autoimmune/inflammatory diseases.
Additionally, EMD Serono is one of the first biopharmaceutical companies in Massachusetts to announce a significant investment in the Commonwealth since Governor Deval Patrick proposed the Life Sciences Initiative in May 2007, a $1B investment supporting the biopharmaceutical industry.
"I am delighted that EMD Serono has decided to expand in Billerica,"
said Governor Patrick. "The region's tremendous talent and resources will
now be at EMD Serono's disposal in their work to improve the quality of
life for people living with serious diseases. Today's announcement
exemplifies the value of the Life Sciences Initiative in encouraging
|SOURCE EMD Serono, Inc.|
Copyright©2008 PR Newswire.
All rights reserved